Bryan Garnier - Remy Cointreau SA (RCOP.PA) RÃ‰MY COINTREAU: No signs of slowdown in Q3 and strong end to the year expected | BUY | EUR126(

Report

Bryan Garnier

Virginie Roumage

RÃ‰MY COINTREAU: No signs of slowdown in Q3 and strong end to the year expected | BUY | EUR126(

RÃ‰MY COINTREAU - BUY | EUR126(+22%)
No signs of slowdown in Q3 and strong end to the year expected

Sales grew 20% in China in Q3 excluding the CNY
Improved visibility and diversification in China are reassuring
Sales in the US accelerated in Q3, with a double digit growth
The outlook is definitively positive

23/01/2019 3 EN

Underlying

Remy Cointreau SA

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Virginie Roumage

Other Reports on these Companies

Bryan Garnier

RÉMY COINTREAU | NEUTRAL | EUR210 VS. EUR205 Short term upside into Q1 sales

Remy Cointreau enjoys many positive catalysts. Beyond underlying growth in the spirits markets, Remy Cointreau is well positioned through its high-end brand portfolio enabling it to outperform the premium sprits segment. We are optimistic for Q1 2022/23 sales growth as we anticipate a 20% organic revenue increase, driven by a positive effect from both volumes and value. Remy Martin (72% of group sales) should lead this growth. Furthermore, given recent weakness in the EUR, FX is set to provide be a clear tailwind for Q1 and probably for FY 2022/23. We are also quite confident in FY 2022/23 sal...

July 19, 2022 July 19, 2022 1 EN

Bryan Garnier

RÉMY COINTREAU: Confidence of the management for the current year | NEUTRAL | EUR205

RÉMY COINTREAU - NEUTRAL | EUR205 Confidence of the management for the current year 210bp EBIT margin gain in FY 2021/22 FY 2023 sales growth should be boosted by new price increase Neutral recommendation reiterated

June 2, 2022 June 2, 2022 1 EN

Bryan Garnier

RÉMY COINTREAU NEUTRAL | EUR197 FY sales in line with expectations. Strong growth in FY EBIT not quantified at this stage

º Q4 sales in line with expectations FY 21/22 EBIT set to “grow very strongly”, but management has provided no precise figures Neutral recommendation reiterated

May 2, 2022 May 2, 2022 1 EN

Egetis: Submits pre-NDA meeting, positive recruitment update

Egetis posted a positive US development update on Emcitate with 15 evaluable patients in the US ReTRIACt phase 3 study (vs 12 at previous update) and has submitted a pre-NDA meeting (Type B) request to the FDA, with plans to initiate the submission of the NDA for tiratricol (Emcitate) this year. As

3h / 31m 3h / 31m 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Faron: Positive FDA feedback sends BEX into a registrational phase 2/3 study

Faron is advancing bexmarilimab (BEX) into a registrational phase 2/3 trial in HR-MDS following a positive EOP2 meeting with the FDA. We view the feedback of broadly positive, as the trial design remains largely unchanged, with a single study expected to support approvals in both frontline and rela

3h / 49m 3h / 49m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Fastned: H1 results, GM recovery, roll-out acceleration expected in H2

This morning, Fastned published its H1 2025 key metrics and number of operating stations. H1 sales came in at EUR54.3m (+44% YoY), implying revenue of EUR26.3m in Q2 2025 (-9% vs cons. at EUR28.9m) and pointing to an annual run-rate of at least EUR108m (vs cons. at EUR130.8m for FY25 and STFe EUR13

August 14, 2025 August 14, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

RÃ‰MY COINTREAU: No signs of slowdown in Q3 and strong end to the year expected | BUY | EUR126(

RÉMY COINTREAU | NEUTRAL | EUR210 VS. EUR205 Short term upside into Q1 sales

RÉMY COINTREAU: Confidence of the management for the current year | NEUTRAL | EUR205

RÉMY COINTREAU NEUTRAL | EUR197 FY sales in line with expectations. Strong growth in FY EBIT not quantified at this stage

Egetis: Submits pre-NDA meeting, positive recruitment update

Faron: Positive FDA feedback sends BEX into a registrational phase 2/3 study

Fastned: H1 results, GM recovery, roll-out acceleration expected in H2

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe